IP Library › Granted Patent US 12,312,412
Granted Patent B2
US 12,312,412 · App. 17/323,884 · Granted May 27, 2025

MAGEB2 binding constructs

Inventors: Ian Nevin Foltz (Burnaby, CA); Weihsu Claire Chen (Vancouver, CA); Lars Gaedtke (Munich, DE); Susmith Mukund (Foster City, CA); Tobias Raum (Eurasburg, DE); Heiko Schuster (Tubingen, DE); Kristin Tarbell (Millbrae, CA); Derek E. Piper (Santa Clara, CA); Johannes Brozy (Munich, DE); Markus Muenz (Lenggries, DE); Igor D'Angelo (Carlsbad, CA); Alexander Sternjak (Munich, DE)
Assignees: Amgen Inc.; Amgen Research (Munich) GmbH; Immatics Biotechnologies GmbH
C07K16/30A61P35/00C07K16/2809A61K2039/505C07K2317/31C07K2317/622C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,312,412
App. No.
17/323,884
Granted
May 27, 2025
Kind
B2
Abstract

The present invention relates to antibody constructs comprising a domain which binds to a MAGEB2 peptide complexed with an HLA and optionally, another domain which binds to CD3. Moreover, the invention provides polynucleotides encoding the antibody constructs, vectors comprising said polynucleotides and host cells transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the antibody constructs of the invention, medical uses of said antibody constructs, and kits comprising said antibody constructs.

Claims (21)

1. An isolated antibody construct, wherein the antibody construct comprises:

a) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 439, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 440, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 441, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 223, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 224 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 225; or

b) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 361, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 362, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 363, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 145, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 146 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 147; or

c) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 523, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 524, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 525, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 307, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 308 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 309; or

d) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 331, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 332, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 333, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 115, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 116 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 117; or

e) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 337, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 338, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 339, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 121, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 122 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 123; or

f) a VH region comprising the amino acid sequence of SEQ ID NO: 629, and a VL region comprising the amino acid sequence of SEQ ID NO: 628; or

g) a VH region comprising the amino acid sequence of SEQ ID NO: 577, and a VL region comprising the amino acid sequence of SEQ ID NO: 576; or

h) a VH region comprising the amino acid sequence of SEQ ID NO: 684 685, and a VL region comprising the amino acid sequence of SEQ ID NO: 684 685; or

i) a VH region comprising the amino acid sequence of SEQ ID NO: 557, and a VL region comprising the amino acid sequence of SEQ ID NO: 556; or

j) a VH region comprising the amino acid sequence of SEQ ID NO: 561, and a VL region comprising the amino acid sequence of SEQ ID NO: 560.

2. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 439, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 440, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 441, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 223, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 224 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 225.

3. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 361, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 362, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 363, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 145, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 146 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 147.

4. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 523, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 524, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 525, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 307, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 308 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 309.

5. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 331, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 332, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 333, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 115, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 116 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 117.

6. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 337, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 338, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 339, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 121, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 122 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 123.

7. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising the amino acid sequence of SEQ ID NO: 629, and a VL region comprising the amino acid sequence of SEQ ID NO: 628.

8. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising the amino acid sequence of SEQ ID NO: 577, and a VL region comprising the amino acid sequence of SEQ ID NO: 576.

9. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising the amino acid sequence of SEQ ID NO: 684, and a VL region comprising the amino acid sequence of SEQ ID NO: 685.

10. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising the amino acid sequence of SEQ ID NO: 557, and a VL region comprising the amino acid sequence of SEQ ID NO: 556.

11. The antibody construct of claim 1 , wherein the antibody construct comprises a VH region comprising the amino acid sequence of SEQ ID NO: 561, and a VL region comprising the amino acid sequence of SEQ ID NO: 560.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2022
From: STERNJAK, ALEXANDER
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 060071/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2021
From: GAEDTKE, LARS; RAUM, TOBIAS; BROZY, JOHANNES; MUENZ, MARKUS
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 056351/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2021
From: FOLTZ, IAN NEVIN; CHEN, CLAIRE WEISHU; MUKUND, SUSMITH; TARBELL, KRISTIN; PIPER, DEREK E.; D'ANGELO, IGOR
To: AMGEN INC.
Reel/Frame 056288/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2021
From: GAEDTKE, LARS; RAUM, TOBIAS; BROZY, JOHANNES; MUENZ, MARKUS
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 056418/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: SCHUSTER, HEIKO
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 056281/0070 →
Continuity (3)
Provisional Application 63128773 · Dec 21, 2020
Provisional Application 63027148 · May 19, 2020
Related Publication 20220017636A1 · Jan 20, 2022
References Cited (359)
US 3691016A · Patel · 1972 [cited by applicant]
US 3969287A · Jaworek et al. · 1976 [cited by applicant]
US 4179337A · Davis et al. · 1979 [cited by applicant]
US 4195128A · Hildebrand et al. · 1980 [cited by applicant]
US 4229537A · Hodgins et al. · 1980 [cited by applicant]
US 4247642A · Hirohara et al. · 1981 [cited by applicant]
US 4301144A · Iwashita et al. · 1981 [cited by applicant]
US 4330440A · Ayers et al. · 1982 [cited by applicant]
US 4439196A · Higuchi · 1984 [cited by applicant]
US 4447224A · DeCant, Jr. et al. · 1984 [cited by applicant]
US 4447233A · Mayfield · 1984 [cited by applicant]
US 4475196A · La Zor · 1984 [cited by applicant]
US 4486194A · Ferrara · 1984 [cited by applicant]
US 4487603A · Harris · 1984 [cited by applicant]
US 4496689A · Mitra · 1985 [cited by applicant]
US 4596556A · Morrow et al. · 1986 [cited by applicant]
US 4640835A · Shimizu et al. · 1987 [cited by applicant]
US 4670417A · Iwasaki et al. · 1987 [cited by applicant]
US 4694778A · Learn et al. · 1987 [cited by applicant]
US 4751180A · Cousens et al. · 1988 [cited by applicant]
US 4790824A · Morrow et al. · 1988 [cited by applicant]
US 4791192A · Nakagawa et al. · 1988 [cited by applicant]
US 4816397A · Boss et al. · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 4941880A · Burns · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5064413A · McKinnon et al. · 1991 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5260203A · Ladner et al. · 1993 [cited by applicant]
US 5292658A · Cormier et al. · 1994 [cited by applicant]
US 5312335A · McKinnon et al. · 1994 [cited by applicant]
US 5383851A · McKinnon, Jr. et al. · 1995 [cited by applicant]
US 5399163A · Peterson et al. · 1995 [cited by applicant]
US 5418155A · Cormier et al. · 1995 [cited by applicant]
US 5476996A · Wilson et al. · 1995 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5612205A · Kay et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5625825A · Rostoker et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5643763A · Dunn et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5683888A · Campbell · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5698767A · Wilson et al. · 1997 [cited by applicant]
US 5721367A · Kay et al. · 1998 [cited by applicant]
US 5741668A · Ward et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5777079A · Tsien et al. · 1998 [cited by applicant]
US 5789215A · Berns et al. · 1998 [cited by applicant]
US 5789650A · Lonberg et al. · 1998 [cited by applicant]
US 5804387A · Cormack et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5859205A · Adair et al. · 1999 [cited by applicant]
US 5874299A · Lonberg et al. · 1999 [cited by applicant]
US 5874304A · Zolotukhin et al. · 1999 [cited by applicant]
US 5876995A · Bryan · 1999 [cited by applicant]
US 5877397A · Lonberg et al. · 1999 [cited by applicant]
US 5925558A · Tsien et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5958765A · Brams et al. · 1999 [cited by applicant]
US 5981175A · Loring et al. · 1999 [cited by applicant]
US 6023010A · Krimpenfort et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6114598A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6162963A · Kucherlapati et al. · 2000 [cited by applicant]
US 6255458B1 · Lonberg et al. · 2001 [cited by applicant]
US 6300064B1 · Knappik et al. · 2001 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 6673986B1 · Kucherlapati et al. · 2004 [cited by applicant]
US 6706265B1 · Bolt et al. · 2004 [cited by applicant]
US 7381803B1 · Weiner et al. · 2008 [cited by applicant]
US 7541429B2 · Hildebrand et al. · 2009 [cited by applicant]
US 7718777B2 · Hoogenboom et al. · 2010 [cited by applicant]
US 7728114B2 · Mach et al. · 2010 [cited by applicant]
US 7811828B2 · Lemmel et al. · 2010 [cited by applicant]
US 7994289B2 · Waldmann et al. · 2011 [cited by applicant]
US 9791443B2 · Weinschenk et al. · 2017 [cited by applicant]
US 10064926B2 · Weinschenk et al. · 2018 [cited by applicant]
US 10545154B2 · Weinschenk et al. · 2020 [cited by applicant]
US 10981996B1 · Weidanz et al. · 2021 [cited by applicant]
US 10981997B1 · Weidanz et al. · 2021 [cited by applicant]
US 11017882B2 · Cameron et al. · 2021 [cited by applicant]
US 20030070185A1 · Jakobovits et al. · 2003 [cited by applicant]
US 20030096298A1 · Barnea et al. · 2003 [cited by applicant]
US 20030228308A1 · Zhang et al. · 2003 [cited by applicant]
US 20030228325A1 · Bilsborough et al. · 2003 [cited by applicant]
US 20040033541A1 · Zhang et al. · 2004 [cited by applicant]
US 20050053918A1 · Barnea et al. · 2005 [cited by applicant]
US 20050249743A1 · Boon-Falleur et al. · 2005 [cited by applicant]
US 20090304679A1 · Weidanz · 2009 [cited by applicant]
US 20130210648A1 · Hewitt · 2013 [cited by examiner]
US 20130266565A1 · Jenewein et al. · 2013 [cited by applicant]
US 20140010825A1 · Ravindranath et al. · 2014 [cited by applicant]
US 20140065708A1 · Weidanz · 2014 [cited by applicant]
US 20140302037A1 · Borges et al. · 2014 [cited by applicant]
US 20140308285A1 · Yan et al. · 2014 [cited by applicant]
US 20160193295A1 · Kannan et al. · 2016 [cited by applicant]
US 20160250307A1 · Weinschenk et al. · 2016 [cited by applicant]
US 20170080070A1 · Weinschenk et al. · 2017 [cited by applicant]
US 20180071398A1 · Willemsen et al. · 2018 [cited by applicant]
US 20180154013A1 · Renes et al. · 2018 [cited by applicant]
US 20180179283A1 · Peled Kamar et al. · 2018 [cited by applicant]
US 20190000947A1 · Weinschenk et al. · 2019 [cited by applicant]
US 20190071502A1 · Weidanz · 2019 [cited by applicant]
US 20190092834A1 · Hayes et al. · 2019 [cited by applicant]
US 20190127436A1 · Tribble et al. · 2019 [cited by applicant]
US 20190135892A1 · Tribble et al. · 2019 [cited by applicant]
US 20190144521A1 · Tribble et al. · 2019 [cited by applicant]
US 20200276237A1 · Shiku et al. · 2020 [cited by applicant]
US 20200291116A1 · Weidanz · 2020 [cited by applicant]
US 20200291127A1 · Weidanz · 2020 [cited by applicant]
US 20200291128A1 · Weidanz · 2020 [cited by applicant]
US 20200325244A1 · Weidanz · 2020 [cited by applicant]
US 20200399377A1 · Weidanz · 2020 [cited by applicant]
US 20210147550A1 · Jooss et al. · 2021 [cited by applicant]
US 20210147572A1 · Weidanz · 2021 [cited by applicant]
US 20210196806A1 · Yelensky et al. · 2021 [cited by applicant]
US 20210230278A1 · Weinzierl et al. · 2021 [cited by applicant]
US 20210253713A1 · Weidanz · 2021 [cited by applicant]
US 20230406929A1 · Rau et al. · 2023 [cited by applicant]
EP 0171496B1 · 1986 [cited by applicant]
EP 0173494A2 · 1986 [cited by applicant]
EP 0183070B1 · 1986 [cited by applicant]
EP 0239400B1 · 1987 [cited by applicant]
EP 0244234B1 · 1987 [cited by applicant]
EP 0402226A1 · 1990 [cited by applicant]
EP 0463151B1 · 1992 [cited by applicant]
EP 0546073B1 · 1993 [cited by applicant]
GB 2177096A · 1987 [cited by applicant]
JP 3068180B2 · 1992 [cited by applicant]
JP 3068506B2 · 1998 [cited by applicant]
JP 3068507B2 · 1998 [cited by applicant]
WO WO8705330A1 · 1987 [cited by applicant]
WO WO8801649A1 · 1988 [cited by applicant]
WO WO8809344A1 · 1988 [cited by applicant]
WO WO9203918A1 · 1992 [cited by applicant]
WO WO9215673A1 · 1992 [cited by applicant]
WO WO9222645A1 · 1992 [cited by applicant]
WO WO9222647A1 · 1992 [cited by applicant]
WO WO9222670A1 · 1992 [cited by applicant]
WO WO9312227A1 · 1993 [cited by applicant]
WO WO9400569A1 · 1994 [cited by applicant]
WO WO9402602A1 · 1994 [cited by applicant]
WO WO9410308A1 · 1994 [cited by applicant]
WO WO9425585A1 · 1994 [cited by applicant]
WO WO9507463A1 · 1995 [cited by applicant]
WO WO9614436A1 · 1996 [cited by applicant]
WO WO9633735A1 · 1996 [cited by applicant]
WO WO9634096A1 · 1996 [cited by applicant]
WO WO9713852A1 · 1997 [cited by applicant]
WO WO9814605A1 · 1998 [cited by applicant]
WO WO9824884A1 · 1998 [cited by applicant]
WO WO9824893A2 · 1998 [cited by applicant]
WO WO9826277A2 · 1998 [cited by applicant]
WO WO9852976A1 · 1998 [cited by applicant]
WO WO9949019A2 · 1999 [cited by applicant]
WO WO9954440A1 · 1999 [cited by applicant]
WO WO00006605A2 · 2000 [cited by applicant]
WO WO0034317A2 · 2000 [cited by applicant]
WO WO0076310A1 · 2000 [cited by applicant]
WO WO02094981A2 · 2002 [cited by applicant]
WO WO0347336A2 · 2003 [cited by applicant]
WO WO03070752A2 · 2003 [cited by applicant]
WO WO2005040220A1 · 2005 [cited by applicant]
WO WO2006138181A2 · 2006 [cited by applicant]
WO WO2007042261A2 · 2007 [cited by applicant]
WO WO2007098420A1 · 2007 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2009026547A1 · 2009 [cited by applicant]
WO WO2009108372A2 · 2009 [cited by applicant]
WO WO2009127691A1 · 2009 [cited by applicant]
WO WO2009151487A1 · 2009 [cited by applicant]
WO WO2010037838A2 · 2010 [cited by applicant]
WO WO2011051489A2 · 2011 [cited by applicant]
WO WO2012059486A1 · 2012 [cited by applicant]
WO WO2012150319A1 · 2012 [cited by applicant]
WO WO2013026833A1 · 2013 [cited by applicant]
WO WO2013026837A1 · 2013 [cited by applicant]
WO WO2013075066A2 · 2013 [cited by applicant]
WO WO2013135896A1 · 2013 [cited by applicant]
WO WO2014072481A1 · 2014 [cited by applicant]
WO WO2014144722A2 · 2014 [cited by applicant]
WO WO2014151910A1 · 2014 [cited by applicant]
WO WO2015048272A1 · 2015 [cited by applicant]
WO WO2016199140A1 · 2016 [cited by applicant]
WO WO2016199141A2 · 2016 [cited by applicant]
WO WO2017174824A1 · 2017 [cited by applicant]
WO WO2018140525A1 · 2018 [cited by applicant]
WO WO2018225732A1 · 2018 [cited by applicant]
WO WO2019036688A1 · 2019 [cited by applicant]
WO WO2019140196A1 · 2019 [cited by applicant]
WO WO2019165307A1 · 2019 [cited by applicant]
WO WO2019204683A1 · 2019 [cited by applicant]
WO WO2019226941A1 · 2019 [cited by applicant]
WO WO2020023548A1 · 2020 [cited by applicant]
WO WO2021122875A1 · 2021 [cited by applicant]
Almagro JC, Fransson J. Humanization of antibodies. Front Biosci. Jan. 1, 2008;13:1619-33. (Year: 2008). [cited by examiner]
Kussie et al. A single engineered amino acid substitution changes antibody fine specificity.J Immunol. Jan. 1, 1994;152(1):146-52. (Year: 1994). [cited by examiner]
Edwards et al. The remarkable flexibility of the human antibody repertoire;isolation of over one thousand different antibodies to a single protein,BLyS. J Mol Biol Nov. 14, 2003;334(1):103-18. (Year: 2003). [cited by examiner]
Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. Phenix: building new software for automated crystallographic structure determination. Acta C… [cited by applicant]
Altschul et al. (J Mol Biol. Oct. 5, 1990;215(3):403-10.). [cited by applicant]
Altschul et al., (Methods Enzymol. 1996; 266:460-80). [cited by applicant]
Altschul et al., (Nucleic Acids Res. Sep. 1, 1997;25(17):3389-402). [cited by applicant]
Aplin and Wriston, 1981, CRC Crit. Rev. Biochem., pp. 259-306. [cited by applicant]
Arakawa T. et al., Pharm Res. Mar. 1991;8(3):285-91. [cited by applicant]
Artsaenko et al. (1995) The Plant J 8: 745-750. [cited by applicant]
Bird (1988) Science vol. 242: pp. 423-426. [cited by applicant]
Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. Oct. 8-14, 1987;329(6139):512-8. [cited by applicant]
Brühl, Immunol., (2001), 166, 2420-2426. [cited by applicant]
Cano et al., “Common and Well-Documented HLA Alleles”, Human Immunology, vol. 68, Issue 5, May 2007, pp. 392-417. [cited by applicant]
Carter et al. (Biotechnology (NY) Feb. 1992;10(2):163-7). [cited by applicant]
Chalfie et al., 1994, Science 263:802-805. [cited by applicant]
Chames et al., “Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-FAB library,” PNAS, 2000, vol. 97, No. 14, pp. 7969-7974. [cited by applicant]
Chang et al., “A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias,” Blood, 2015. [cited by applicant]
Cheadle et al. (Mol Immunol (1992) 29, 21-30). [cited by applicant]
Chothia et al., J. Mol. Biol, 1987, 196: 901-917. [cited by applicant]
Chothia et al., Nature, 1989, 342: 877-883. [cited by applicant]
Clackson et al., Nature, 352: 624-628 (1991). [cited by applicant]
Cohen et al., “Direct Phenotypic Analysis of Human MGC Class I Antigen Presentation: Visualization, Quantitation, and In Situ Detection of Human Viral Epitopes Using Peptide-Specific, MHC-Restricted Human Recombinant An… [cited by applicant]
Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), 77-96. [cited by applicant]
Cook, G.P. et al. (1995) Immunol. Today vol. 16 (5): 237-242. [cited by applicant]
Cunningham B.C. and Wells J.A. (Science. Jun. 2, 1989;244(4908):1081-5). [cited by applicant]
Dall'Acqua et al. (Biochem. (1998) 37, 9266-9273). [cited by applicant]
Dao et al., “Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody”, Sci Transl Med. 2013. [cited by applicant]
Dao et al., “Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1”, Nat. Biotechnol, Oct. 2015. [cited by applicant]
Delano, W.L. The PyMOL Molecular Graphics System. (Palo Alto, 2002); https://wires.onlinelibrary.wiley.com/doi/10.1002/wcms.1298. [cited by applicant]
Denkberg et al., “Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity”, PNAS, 2002… [cited by applicant]
Devereux et al. (Nucleic Acids Res. Jan. 11, 1984;12(1 Pt 1):387-95. [cited by applicant]
Duksin et al., 1982, J. Biol. Chem. 257:3105. [cited by applicant]
Edge et al., 1981, Anal. Biochem. 118: pp. 131-137. [cited by applicant]
Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. Dec. 2004; 60(Pt 12 Pt 1):2126-32. [cited by applicant]
Epel et al., “Targeting TARP, a novel breast and prostate tumor-associated antigen, with T-cell receptor-like human recombinant antibodies”, Eur J Immunol, 2008. [cited by applicant]
Fan, Gaowei; Wang, Zujian; Hao, Mingju; Li, Jinming (2015). “Bispecific antibodies and their applications”. Journal of Hematology & Oncology. 8: 130. [cited by applicant]
Fanslow et al., 1994, Semin. Immunol. 6:267-78. [cited by applicant]
Fecker et al. (1996) Plant Mol Biol 32: 979-986. [cited by applicant]
Feng and Doolittle (J Mol Evol. 1987;25(4):351-60);. [cited by applicant]
George et. al“Current Methods in Sequence Comparison and Analysis,” Macromolecular Sequencing and Synthesis, Selected Methods and Applications edited by David H. Schlesinger, pp. 127-149 (1988), Alan R. Liss, Inc. [cited by applicant]
Graham et al., J. Gen Virol. 36 : 59-72 (1977). [cited by applicant]
Green and Jakobovits J. Exp. Med. vol. 188: pp. 483-495 (1998). [cited by applicant]
Green et al. (1994) Nature Genetics 7:13-21. [cited by applicant]
Gundlach et al., “Specificity and Degeneracy of Minor Histocompatibility Antigen-Specific MHC-Restricted CTL”, The Journal of Immunology, 1996, pp. 3645-3651. [cited by applicant]
Hakimuddin Sojar et al., 1987, Arch. Biochem. Biophys. 259:52-57. [cited by applicant]
Eds. Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. [cited by applicant]
Eds. Harlow et al., Using Antibodies: a laboratory manual, CSHL Press (1999); table of contents. [cited by applicant]
Hawkins et al. J. Mol. Biol. vol. 226, 889-896 (1992). [cited by applicant]
Hawkins et al., “An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer”, The Journal of Immunology, 2011, pp. 6607-6616. [cited by applicant]
Heim et al., 1996, Curr. Biol. 6:178-182. [cited by applicant]
Held et al., Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragements, EUR J. Immunol, 2004, pp. 2919-2929. [cited by applicant]
Hiatt et al., Nature (1989) 342: 76-78. [cited by applicant]
Higgins and Sharp (Comput Appl Biosci. Apr. 1989;5(2):151-3). [cited by applicant]
Holland et al., “Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA”, The Journal of Clinical Investigation, 2020. [cited by applicant]
Holliger, Philipp et al., (Jul. 1993) Proceedings of the National Academy of Sciences of the United States of America 90 (14): 6444-8. [cited by applicant]
Hoppe et al., 1994, FEBS Letters 344: pp. 191-195. [cited by applicant]
Hoydahl et al., “Targeting the MHC Ligandome by Use of TCR-Like Antibodies”, [cited by applicant]
Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: pp. 5879-5883. [cited by applicant]
Hwai-Chen Guo et al., Nature 360(6402):364-66 (1992). [cited by applicant]
Hwang, W.Y. et al., Methods. 2005; pp. 35-42. [cited by applicant]
Ichiki et al., 1993, J. Immunol. 150:5408-5417. [cited by applicant]
Eds. Honio et al., Immunoglobulin Genes, 2nd ed., Academic Press, San Diego, CA, 1995. [cited by applicant]
International Search Report for PCT/US2021/032961 mailed Nov. 5, 2021. [cited by applicant]
Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. [cited by applicant]
Jones et al., Nature, vol. 321: pp. 522-525 (1986). [cited by applicant]
Karlin and Altschul (Proc Natl Acad Sci U S A. Jun. 15, 1993;90(12):5873-7). [cited by applicant]
Kendrick et al., “Physical stabilization of proteins in aqueous solution” in: Rational Design of Stable Protein Formulations-Theory and Practice (Carpenter and Manning, eds.) Pharmaceutical Biotechnology. 13: 61-84 (200… [cited by applicant]
Kim et al., “A novel T cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice”, Eur J Immunol, 2014. [cited by applicant]
Kipriyanov, J. Mol. Biol., (1999), 293, 41-56. [cited by applicant]
Klechevsky et al., “Antitumor Activity of Immunotoxins with T-cell Receptor-like Specificity against Human Melanoma Xenografts”, Cancer Res 2008. [cited by applicant]
Klinger et al., Immunol Reviews 2016. [cited by applicant]
Köhler et al., Nature, vol. 256: 495-497 (1975). [cited by applicant]
Kozbor, Immunology Today vol. 4, No. 3 (1983), pp. 72-79. [cited by applicant]
Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. Sep. 21;372(3):774-97 (2007). [cited by applicant]
Kufer P. et al., (2004) Trends in Biotechnology 22(5):238-244. [cited by applicant]
Kufer, Cancer Immunol. Immunother., (1997), 45, 193-197. [cited by applicant]
Landschulz et al., 1988, Science 240: pp. 1759-1764. [cited by applicant]
Lee and Potts, J. Mol. Biol., 2018. [cited by applicant]
Lev et al., Cancer Research, 2002, pp. 3184-3194. [cited by applicant]
Little, Recombinant Antibodies for Immunotherapy, Cambridge University Press 2009. [cited by applicant]
Löffler, Blood, (2000), 95, 6, 2098-2103. [cited by applicant]
Lowman et al., Biochemistry 30, 10832- 10837 (1991). [cited by applicant]
MacCallum et al., J. Mol. Biol, 1996, 262: 732-745. [cited by applicant]
Mack et al. Tissue Antigens. Apr. 2013; 81(4): 194-203. [cited by applicant]
Mack, J. Immunol. (1997), 158, 3965-3970. [cited by applicant]
Mack, PNAS, (1995), 92, 7021-7025. [cited by applicant]
Makler et al., European Journal of Immunology, 2010; pp. 1552-1565. [cited by applicant]
Malmborg, J. Immunol. Methods 183 (1995), 7-13. [cited by applicant]
Marks et al., J. Mol. Biol., 222: 581-597 (1991). [cited by applicant]
Martin and Thornton, J. Mol. Biol, 1996, 263: 800-815. [cited by applicant]
Mather et al., Annals N. Y Acad. Sci. (1982) 383: 44-68). [cited by applicant]
Mather, Biol. Reprod. 23: 243-252 (1980). [cited by applicant]
McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. Apr. 2005;61(Pt 4):458-64. [cited by applicant]
Mendez et al. Nature Genetics 15:146-156 (1997). [cited by applicant]
Michaeli et al., The Journal of Immunology, 2009, pp. 6328-6341. [cited by applicant]
Morrison (1985) Science 229:1202-1207. [cited by applicant]
Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984). [cited by applicant]
Morrison KL & Weiss GA. (Cur Opin Chem Biol. Jun. 2001;5(3):302-7). [cited by applicant]
Needleman and Wunsch (J Mol Biol. Mar. 1970;48(3):443-53),. [cited by applicant]
Neethling et al., “Assessing vaccine potency using TCRmimic antibodies”, Vaccine, 2008, pp. 3092-3102. [cited by applicant]
Nolan et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:2603-2607. [cited by applicant]
Oi et al. (1986) BioTechniques vol. 4, No. 3, pp. 214-221. [cited by applicant]
Olsson et al., Meth. Enzymol., vol. 92: pp. 3-16, 1982. [cited by applicant]
Owen et al. (1992) Bio/Technology 10: 790-794. [cited by applicant]
Padlan, Molecular Immunology, 31(3), 169-217 (1993). [cited by applicant]
Pearson and Lipman (Proc Natl Acad Sci USA. Apr. 1988;85(8):2444-8. [cited by applicant]
Peche et al., The Journal of Biological Chemistry, 2015, pp. 29652-39662. [cited by applicant]
Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994). [cited by applicant]
Polakova et al., The Journal of Immunology, 2000, pp. 5703-5712. [cited by applicant]
Porgador et al., Immunity, 1997, vol. 6, pp. 715-726. [cited by applicant]
Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992). [cited by applicant]
Ed.: Duebel, S. and Kontermann, R., Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual Springer-Verlag, Heidelberg. [cited by applicant]
Raag and Whitlow (FASEB (1995) 9(1), 73-80). [cited by applicant]
Randolph and Jones, Pharm Biotechnol. 2002; 13:159-75. [cited by applicant]
Reichmann et al., Nature, 332: 323-329 (1988). [cited by applicant]
Remington's Pharmaceutical Sciences, 18″ Edition, 1990, Mack Publishing Company. [cited by applicant]
Roberts, Trends Biotechnol. Jul. 2014;32(7):372-80. [cited by applicant]
Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001. [cited by applicant]
Sastry et al., Journal of Virology, 2011, vol. 85, No. 5, Stewa pp. 1935-1942. [cited by applicant]
Schier, Human Antibodies Hybridomas 7 (1996), 97-105. [cited by applicant]
Schlereth et al. (Cancer Immunol. Immunother. 20 (2006), 1-12). [cited by applicant]
Fremont et al., Science, vol. 257:919-27 (1992). [cited by applicant]
Skerra et al. (1988) Science 240:1038-1041. [cited by applicant]
Smith (1985) Science 228:1315-1317. [cited by applicant]
Smith and Waterman, 1981, Adv. Appl. Math. 2: pp. 482-489. [cited by applicant]
Songsivilai & Lachmann, Clin. Exp. Immunol. 79:315-321 (1990). [cited by applicant]
Stauber, 1998, Biotechniques 24:462-471. [cited by applicant]
Stewart-Jones et al., PNAS, 2009, vol. 106, No. 14, pp. 5784-5788. [cited by applicant]
Storoni LC, McCoy AJ, Read RJ. Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr. Mar. 2004;60(Pt 3):432-8. [cited by applicant]
Stryhn et al., PNAS, 1996, vol. 93, pp. 10338-10342. [cited by applicant]
T. E. Creighton, Proteins: Structure and Molecular Properties, W. H. Freeman & Co., San Francisco, 1983, pp. 70-86. [cited by applicant]
T.G.G. Battye, L. Kontogiannis, O. Johnson, H.R. Powell and A.G.W. Leslie. IMosflm: a new graphical interface for diffraction-image processing with MOSFLM. Acta Cryst. D67, 271-81 (2011). [cited by applicant]
Takeda et al., Nature 314:452, 1985. [cited by applicant]
Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80: 7308-7312, 1983. [cited by applicant]
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-3 (1994). [cited by applicant]
Thotakura et al., 1987, Meth. Enzymol. 138: pp. 350-359. [cited by applicant]
Tomlinson et al. (1995) EMBO J. vol. 14, No. 18, pp. 4628-4638. [cited by applicant]
Tomlinson, et al. (1992) J. Mol. Biol. 227:776-798. [cited by applicant]
Tynan et al., Nat Immunol 6(11): 1114-22 (2005). [cited by applicant]
Urlaub et al., Proc. Natl. Acad. Sci. USA 77: 4216-4220 (1980). [cited by applicant]
Verma et al., J Immunol, 2011, pp. 3265-3276. [cited by applicant]
Wang, Int J Pharm. Aug. 20, 1999;185(2): 129-88. [cited by applicant]
Ward et al. (1989) Nature vol. 341: pp. 544-546. [cited by applicant]
Weidanz et al., Int Rev Immunol, 2011. [cited by applicant]
Weidanz et al., The Journal of Immunology, 2006, pp. 5088-5097. [cited by applicant]
Written Opinion for PCT/US2021/032961 mailed Nov. 5, 2021. [cited by applicant]
Yang, Fa; Wen, Weihong; Qin, Weijun (2016). “Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies”. International Journal of Molecular Sciences. 18 (1): 48. [cited by applicant]
Z. Otwinowski and W. Minor, “Processing of X-ray Diffraction Data Collected in Oscillation Mode ”, Methods in Enzymology, vol. 276: Macromolecular Crystallography, part A, p. 307-326, 1997,C.W. Carter, Jr. & R.M. Sweet,… [cited by applicant]
Zhu, K, Day, T, Warshaviak, D, Murrett, C, Friesner, R, Pearlman, D. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction, Proteins. 2014, 82(8): 1646-5… [cited by applicant]
Eds. John E. Coligan et al., Current Protocols In Immunology, John Wiley & Sons, Inc., 2001, table of contents only. [cited by applicant]
Editors I. Johnson and M. T.Z. Spence, The Molecular Probes Handbook: A Guide to Fluorescent Probes and Labeling Technologies, 11 [cited by applicant]